LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Article ; Online: Multimodal brain age prediction using machine learning: combining structural MRI and 5-HT2AR PET-derived features.

    Dörfel, Ruben P / Arenas-Gomez, Joan M / Svarer, Claus / Ganz, Melanie / Knudsen, Gitte M / Svensson, Jonas E / Plavén-Sigray, Pontus

    GeroScience

    2024  

    Abstract: To better assess the pathology of neurodegenerative disorders and the efficacy of neuroprotective interventions, it is necessary to develop biomarkers that can accurately capture age-related biological changes in the human brain. Brain serotonin 2A ... ...

    Abstract To better assess the pathology of neurodegenerative disorders and the efficacy of neuroprotective interventions, it is necessary to develop biomarkers that can accurately capture age-related biological changes in the human brain. Brain serotonin 2A receptors (5-HT2AR) show a particularly profound age-related decline and are also reduced in neurodegenerative disorders, such as Alzheimer's disease. This study investigates whether the decline in 5-HT2AR binding, measured in vivo using positron emission tomography (PET), can be used as a biomarker for brain aging. Specifically, we aim to (1) predict brain age using 5-HT2AR binding outcomes, (2) compare 5-HT2AR-based predictions of brain age to predictions based on gray matter (GM) volume, as determined with structural magnetic resonance imaging (MRI), and (3) investigate whether combining 5-HT2AR and GM volume data improves prediction. We used PET and MR images from 209 healthy individuals aged between 18 and 85 years (mean = 38, std = 18) and estimated 5-HT2AR binding and GM volume for 14 cortical and subcortical regions. Different machine learning algorithms were applied to predict chronological age based on 5-HT2AR binding, GM volume, and the combined measures. The mean absolute error (MAE) and a cross-validation approach were used for evaluation and model comparison. We find that both the cerebral 5-HT2AR binding (mean MAE = 6.63 years, std = 0.74 years) and GM volume (mean MAE = 6.95 years, std = 0.83 years) predict chronological age accurately. Combining the two measures improves the prediction further (mean MAE = 5.54 years, std = 0.68). In conclusion, 5-HT2AR binding measured using PET might be useful for improving the quantification of a biomarker for brain aging.
    Language English
    Publishing date 2024-04-26
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2886586-8
    ISSN 2509-2723 ; 2509-2715
    ISSN (online) 2509-2723
    ISSN 2509-2715
    DOI 10.1007/s11357-024-01148-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: In vivo correlation of serotonin transporter and 1B receptor availability in the human brain: a PET study.

    Svensson, Jonas E / Tiger, Mikael / Plavén-Sigray, Pontus / Halldin, Christer / Schain, Martin / Lundberg, Johan

    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

    2022  Volume 47, Issue 10, Page(s) 1863–1868

    Abstract: Synaptic serotonin levels in the brain are regulated by active transport into the bouton by the serotonin transporter, and by autoreceptors, such as the inhibitory serotonin (5-HT) 1B receptor which, when activated, decreases serotonin release. Animal ... ...

    Abstract Synaptic serotonin levels in the brain are regulated by active transport into the bouton by the serotonin transporter, and by autoreceptors, such as the inhibitory serotonin (5-HT) 1B receptor which, when activated, decreases serotonin release. Animal studies have shown a regulatory link between the two proteins. Evidence of such coupling could translate to an untapped therapeutic potential in augmenting the effect of selective serotonin reuptake inhibitors through pharmacological modulation of 5-HT
    MeSH term(s) Animals ; Brain ; Humans ; Positron-Emission Tomography/methods ; Receptor, Serotonin, 5-HT1B/metabolism ; Serotonin/metabolism ; Serotonin Plasma Membrane Transport Proteins/metabolism ; Serotonin Uptake Inhibitors/metabolism ; Serotonin Uptake Inhibitors/pharmacology
    Chemical Substances Receptor, Serotonin, 5-HT1B ; Serotonin Plasma Membrane Transport Proteins ; Serotonin Uptake Inhibitors ; Serotonin (333DO1RDJY)
    Language English
    Publishing date 2022-07-11
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639471-1
    ISSN 1740-634X ; 0893-133X
    ISSN (online) 1740-634X
    ISSN 0893-133X
    DOI 10.1038/s41386-022-01369-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Prediction of brain age using structural magnetic resonance imaging: A comparison of accuracy and test-retest reliability of publicly available software packages.

    Dörfel, Ruben P / Arenas-Gomez, Joan M / Fisher, Patrick M / Ganz, Melanie / Knudsen, Gitte M / Svensson, Jonas E / Plavén-Sigray, Pontus

    Human brain mapping

    2023  Volume 44, Issue 17, Page(s) 6139–6148

    Abstract: Brain age prediction algorithms using structural magnetic resonance imaging (MRI) aim to assess the biological age of the human brain. The difference between a person's chronological age and the estimated brain age is thought to reflect deviations from a ...

    Abstract Brain age prediction algorithms using structural magnetic resonance imaging (MRI) aim to assess the biological age of the human brain. The difference between a person's chronological age and the estimated brain age is thought to reflect deviations from a normal aging trajectory, indicating a slower or accelerated biological aging process. Several pre-trained software packages for predicting brain age are publicly available. In this study, we perform a comparison of such packages with respect to (1) predictive accuracy, (2) test-retest reliability, and (3) the ability to track age progression over time. We evaluated the six brain age prediction packages: brainageR, DeepBrainNet, brainage, ENIGMA, pyment, and mccqrnn. The accuracy and test-retest reliability were assessed on MRI data from 372 healthy people aged between 18.4 and 86.2 years (mean 38.7 ± 17.5 years). All packages showed significant correlations between predicted brain age and chronological age (r = 0.66-0.97, p < 0.001), with pyment displaying the strongest correlation. The mean absolute error was between 3.56 (pyment) and 9.54 years (ENIGMA). brainageR, pyment, and mccqrnn were superior in terms of reliability (ICC values between 0.94-0.98), as well as predicting age progression over a longer time span. Of the six packages, pyment and brainageR consistently showed the highest accuracy and test-retest reliability.
    MeSH term(s) Humans ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Reproducibility of Results ; Magnetic Resonance Imaging/methods ; Brain/diagnostic imaging ; Brain/pathology ; Magnetic Resonance Spectroscopy ; Software
    Language English
    Publishing date 2023-10-16
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1197207-5
    ISSN 1097-0193 ; 1065-9471
    ISSN (online) 1097-0193
    ISSN 1065-9471
    DOI 10.1002/hbm.26502
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Evaluating the effect of rapamycin treatment in Alzheimer's disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol.

    Svensson, Jonas E / Bolin, Martin / Thor, Daniel / Williams, Pete A / Brautaset, Rune / Carlsson, Marcus / Sörensson, Peder / Marlevi, David / Spin-Neto, Rubens / Probst, Monika / Hagman, Göran / Morén, Anton Forsberg / Kivipelto, Miia / Plavén-Sigray, Pontus

    BMC neurology

    2024  Volume 24, Issue 1, Page(s) 111

    Abstract: Background: Rapamycin is an inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, and preclinical data demonstrate that it is a promising candidate for a general gero- and neuroprotective treatment in humans. Results from mouse models ... ...

    Abstract Background: Rapamycin is an inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, and preclinical data demonstrate that it is a promising candidate for a general gero- and neuroprotective treatment in humans. Results from mouse models of Alzheimer's disease have shown beneficial effects of rapamycin, including preventing or reversing cognitive deficits, reducing amyloid oligomers and tauopathies and normalizing synaptic plasticity and cerebral glucose uptake. The "Evaluating Rapamycin Treatment in Alzheimer's Disease using Positron Emission Tomography" (ERAP) trial aims to test if these results translate to humans through evaluating the change in cerebral glucose uptake following six months of rapamycin treatment in participants with early-stage Alzheimer's disease.
    Methods: ERAP is a six-month-long, single-arm, open-label, phase IIa biomarker-driven study evaluating if the drug rapamycin can be repurposed to treat Alzheimer's disease. Fifteen patients will be included and treated with a weekly dose of 7 mg rapamycin for six months. The primary endpoint will be change in cerebral glucose uptake, measured using [
    Discussion: The ERAP study is a clinical trial using in vivo imaging biomarkers to assess the repurposing of rapamycin for the treatment of Alzheimer's disease. If successful, the study would provide a strong rationale for large-scale evaluation of mTOR-inhibitors as a potential disease-modifying treatment in Alzheimer's disease.
    Trial registration: ClinicalTrials.gov ID NCT06022068, date of registration 2023-08-30.
    MeSH term(s) Animals ; Mice ; Humans ; Alzheimer Disease/diagnostic imaging ; Alzheimer Disease/drug therapy ; Alzheimer Disease/complications ; Aging ; Cognition Disorders ; Positron-Emission Tomography/methods ; Glucose/metabolism ; TOR Serine-Threonine Kinases ; Amyloid beta-Peptides/cerebrospinal fluid ; Clinical Trials, Phase II as Topic
    Chemical Substances Glucose (IY9XDZ35W2) ; TOR Serine-Threonine Kinases (EC 2.7.11.1) ; Amyloid beta-Peptides
    Language English
    Publishing date 2024-04-04
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2041347-6
    ISSN 1471-2377 ; 1471-2377
    ISSN (online) 1471-2377
    ISSN 1471-2377
    DOI 10.1186/s12883-024-03596-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Early stopping in clinical PET studies: How to reduce expense and exposure.

    Svensson, Jonas E / Schain, Martin / Knudsen, Gitte M / Ogden, R Todd / Plavén-Sigray, Pontus

    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

    2021  Volume 41, Issue 11, Page(s) 2805–2819

    Abstract: Clinical positron emission tomography (PET) research is costly and entails exposing participants to radioactivity. Researchers should therefore aim to include just the number of subjects needed to fulfill the purpose of the study. In this tutorial we ... ...

    Abstract Clinical positron emission tomography (PET) research is costly and entails exposing participants to radioactivity. Researchers should therefore aim to include just the number of subjects needed to fulfill the purpose of the study. In this tutorial we show how to apply
    MeSH term(s) Adult ; Bayes Theorem ; Case-Control Studies ; Computer Simulation/statistics & numerical data ; Early Termination of Clinical Trials/ethics ; Early Termination of Clinical Trials/methods ; Female ; Humans ; Male ; Middle Aged ; Positron-Emission Tomography/adverse effects ; Positron-Emission Tomography/economics ; Positron-Emission Tomography/statistics & numerical data ; Radiation Exposure/adverse effects ; Radiation Exposure/prevention & control ; Research Design ; Sample Size
    Language English
    Publishing date 2021-05-21
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 604628-9
    ISSN 1559-7016 ; 0271-678X
    ISSN (online) 1559-7016
    ISSN 0271-678X
    DOI 10.1177/0271678X211017796
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Serotonin transporter availability increases in patients recovering from a depressive episode.

    Svensson, Jonas E / Svanborg, Cecilia / Plavén-Sigray, Pontus / Kaldo, Viktor / Halldin, Christer / Schain, Martin / Lundberg, Johan

    Translational psychiatry

    2021  Volume 11, Issue 1, Page(s) 264

    Abstract: Molecular imaging studies have shown low cerebral concentration of serotonin transporter in patients suffering from depression, compared to healthy control subjects. Whether or not this difference also is present before disease onset and after remission ( ...

    Abstract Molecular imaging studies have shown low cerebral concentration of serotonin transporter in patients suffering from depression, compared to healthy control subjects. Whether or not this difference also is present before disease onset and after remission (i.e. a trait), or only at the time of the depressive episode (i.e. a state) remains to be explored. We examined 17 patients with major depressive disorder with positron emission tomography using [
    MeSH term(s) Brain/diagnostic imaging ; Brain/metabolism ; Cross-Sectional Studies ; Depressive Disorder, Major/diagnostic imaging ; Depressive Disorder, Major/therapy ; Humans ; Positron-Emission Tomography ; Raphe Nuclei/metabolism ; Serotonin Plasma Membrane Transport Proteins/metabolism
    Chemical Substances Serotonin Plasma Membrane Transport Proteins
    Language English
    Publishing date 2021-05-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2609311-X
    ISSN 2158-3188 ; 2158-3188
    ISSN (online) 2158-3188
    ISSN 2158-3188
    DOI 10.1038/s41398-021-01376-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Low convergent validity of [

    Freiburghaus, Tove / Svensson, Jonas E / Matheson, Granville J / Plavén-Sigray, Pontus / Lundberg, Johan / Farde, Lars / Cervenka, Simon

    NeuroImage

    2020  Volume 226, Page(s) 117523

    Abstract: Dopamine D2 receptors (D2-R) in extrastriatal brain regions are of high interest for research in a wide range of psychiatric and neurologic disorders. Pharmacological competition studies and test-retest experiments have shown high validity and ... ...

    Abstract Dopamine D2 receptors (D2-R) in extrastriatal brain regions are of high interest for research in a wide range of psychiatric and neurologic disorders. Pharmacological competition studies and test-retest experiments have shown high validity and reliability of the positron emission tomography (PET) radioligand [
    MeSH term(s) Brain/metabolism ; Brain Mapping/methods ; Carbon Radioisotopes/metabolism ; Carbon Radioisotopes/pharmacology ; Dopamine Antagonists/metabolism ; Dopamine Antagonists/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Positron-Emission Tomography/methods ; Pyrrolidines/metabolism ; Pyrrolidines/pharmacology ; Raclopride/metabolism ; Raclopride/pharmacology ; Radioligand Assay/methods ; Radiopharmaceuticals/metabolism ; Radiopharmaceuticals/pharmacology ; Receptors, Dopamine D2/analysis ; Salicylamides/metabolism ; Salicylamides/pharmacology
    Chemical Substances Carbon Radioisotopes ; Carbon-11 ; Dopamine Antagonists ; Pyrrolidines ; Radiopharmaceuticals ; Receptors, Dopamine D2 ; Salicylamides ; FLB 457 (107188-66-9) ; Raclopride (430K3SOZ7G)
    Language English
    Publishing date 2020-11-02
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1147767-2
    ISSN 1095-9572 ; 1053-8119
    ISSN (online) 1095-9572
    ISSN 1053-8119
    DOI 10.1016/j.neuroimage.2020.117523
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Validity and reliability of extrastriatal [

    Svensson, Jonas E / Schain, Martin / Plavén-Sigray, Pontus / Cervenka, Simon / Tiger, Mikael / Nord, Magdalena / Halldin, Christer / Farde, Lars / Lundberg, Johan

    NeuroImage

    2019  Volume 202, Page(s) 116143

    Abstract: ...

    Abstract [
    MeSH term(s) Adult ; Brain/diagnostic imaging ; Dopamine D2 Receptor Antagonists/pharmacokinetics ; Humans ; Male ; Positron-Emission Tomography/methods ; Quetiapine Fumarate/pharmacokinetics ; Raclopride/pharmacokinetics ; Radioligand Assay ; Receptors, Dopamine D2/metabolism ; Receptors, Dopamine D3/antagonists & inhibitors ; Receptors, Dopamine D3/metabolism ; Reproducibility of Results ; Young Adult
    Chemical Substances DRD2 protein, human ; Dopamine D2 Receptor Antagonists ; Receptors, Dopamine D2 ; Receptors, Dopamine D3 ; Quetiapine Fumarate (2S3PL1B6UJ) ; Raclopride (430K3SOZ7G)
    Language English
    Publishing date 2019-08-29
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1147767-2
    ISSN 1095-9572 ; 1053-8119
    ISSN (online) 1095-9572
    ISSN 1053-8119
    DOI 10.1016/j.neuroimage.2019.116143
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: In response to the letter "[

    Svensson, Jonas E / Schain, Martin / Plavén-Sigray, Pontus / Cervenka, Simon / Tiger, Mikael / Nord, Magdalena / Halldin, Christer / Farde, Lars / Lundberg, Johan

    NeuroImage

    2019  Volume 207, Page(s) 116371

    MeSH term(s) Brain ; Carbon Radioisotopes ; Humans ; Raclopride ; Reproducibility of Results
    Chemical Substances Carbon Radioisotopes ; Carbon-11 ; Raclopride (430K3SOZ7G)
    Language English
    Publishing date 2019-11-20
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1147767-2
    ISSN 1095-9572 ; 1053-8119
    ISSN (online) 1095-9572
    ISSN 1053-8119
    DOI 10.1016/j.neuroimage.2019.116371
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top